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1. Introduction
In recent years, a new generation of potent compounds, synthetically-derived cannabinoids, 
has ranked among the most widely abused illicit substances in the United States and around 
the world, second only to natural cannabis (Gunderson, 2013; Gunderson et al., 2014). 
Synthetic cannabinoids (SCBs), the major active constituents of herbal “Spice” preparations, 
are a structurally diverse family of laboratory-derived chemicals that were originally created 
for investigating the mechanisms of cannabinoid receptor binding and signaling 
(Mechoulam and Carlini, 1978). In an effort by manufacturers of recreational SCB’s to 
increase potency and evade detection, new structural derivatives are emerging at a staggering 
pace, making it exceedingly challenging for law enforcement to monitor or control their 
distribution (Underwood, 2015).
Dangerous health effects are frequently reported among SCB users (McGuinness and 
Newell, 2012). Due to the demonstrated toxicity of SCBs in adults, prenatal exposures are 
also expected to be harmful. Despite accumulating epidemiological evidence, cannabinoids 
remain the most commonly abused illicit substances by pregnant women worldwide (Brown 
and Graves, 2013; Calvigioni et al., 2014; Holbrook and Rayburn, 2014), and international 
trends of illicit drug use over the last few decades reflect an increasing popularity of 
cannabinoids (both natural and synthetic) among women of reproductive age (Papaseit et al., 
2014; Schneir et al., 2011). This usage, combined with the fact that approximately one half 
of all pregnancies, worldwide, are unintentional/unplanned; (Finer and Zolna, 2014; Singh et 
al., 2010) means that the likelihood of inadvertent early prenatal exposure is high. Taking 
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this into consideration, study of the developmental toxicity/teratogenic potential of SCBs 
requires particular attention.
The majority of our current understanding of prenatal cannabinoid effects stems from earlier 
studies conducted in humans and animal models with marijuana or its psychoactive 
constituents. The results of human cannabinoid developmental toxicology/teratogenicity 
studies, most of which were published in the 1980s and 90s, show an association between 
marijuana use and growth retardation, distal limb defects, craniofacial abnormalities 
comparable to those in fetal alcohol syndrome, behavioral abnormalities, and occasionally, 
perinatal death (Gibson et al., 1983; Hingson et al., 1982). First trimester marijuana use has 
been noted to be particularly damaging (Gibson et al., 1983). Animal-based teratogenicity 
studies involving crude marijuana extracts have yielded confounding results. In part, this has 
been the result of interstudy variability in drug concentrations and developmental stage at 
the time of exposure. Among the teratogenicity-positive results are those from a study of rats 
that were administered cannabis at an intraperitoneal dosage of 4.2 mg/kg body weight 
between gestational days 1–6. Along with an increased incidence of fetal resorption and 
decreased fetal weight and size, a high incidence of syndactyly, encephalocele, phocomelia, 
and abdominal viscera eventration were reported (Persaud and Ellington, 1967). Similar 
congenital malformations were reported in guinea pigs and rabbits that were subcutaneously 
administered cannabis extract at dosages of 250 or 500 mg/kg during early gestation (Geber 
and Schramm, 1969).
The isolation and elucidation of Δ9-THC as a main psychoactive ingredient of cannabis 
(Mechoulam and Gaoni, 1967) and administration of its pure form allowed greater insight 
into the potential teratogenicity of cannabinoids. Importantly, a study involving multiple 
strains of mice and single intravenous (10–20 mg/kg), subcutaneous (6.25–150 mg/kg), or 
intragastric (100–400 mg/kg) treatments of Δ9-THC showed that while low doses were not 
overtly teratogenic, a consistent, reproducible array of gross morphological abnormalities 
occurred following administration of relatively high doses of Δ9-THC at distinct critical 
stages of development. These endpoints occurred irrespective of drug administration route 
(Joneja, 1976). It was later determined that, as a lipid soluble compound, Δ9-THC readily 
crosses the placenta and is recoverable from fetal animal compartments following 
documented exposure, with maternal and fetal plasma containing equivalent concentrations 
of Δ9-THC 3 hours following maternal drug administration (Bailey et al., 1987). While these 
findings raise considerable human health concerns, a number of investigations have led to 
the opposing conclusion that neither Δ9-THC nor cannabis is teratogenic (Banerjee et al., 
1975; Borgen et al., 1971). It has been noted that the dosages of marijuana and/or Δ9-THC 
extracts used to cause congenital malformations in many of these early teratology studies 
were above those reported in human users (Hunault et al., 2008). However, given that 
average Δ9-THC concentrations in cannabis have increased greatly in the time since many of 
these experiments were performed, this conclusion may not be appropriate. Over the past 15 
years, forms of cannabis have been developed that contain four to five times as much Δ9-
THC as in the past (Downey and Verster, 2014; Hall and Degenhardt, 2015). Recent changes 
to legislation, as well as changing attitudes towards cannabinoid consumption bring even 
more reason for concern (Hill and Reed, 2013; Metz and Stickrath, 2015).
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In vitro binding and molecular modeling studies have shown that many SCBs found in 
herbal products possess mechanisms of action similar to Δ9-THC (Pertwee et al., 2010; 
Reggio, 2005; Wiley et al., 2014). However, several important differences exist between the 
SCBs and Δ9-THC, many of which contribute to an even greater likelihood that SCBs 
produce dangerous adverse physiological effects in vivo. When compared to Δ9-THC, a 
relatively weak, partial agonist to cannabinoid receptors 1 and 2 (CB1 and CB2, (Breivogel 
and Childers, 2000; Sim et al., 1996; Tao and Abood, 1998), SCBs commonly found in 
herbal Spice preparations (e.g. JWH-018, HU-210, CP-47,497, and CP-55,940), display full 
cannabinoid receptor agonism. This, in turn, results in pharmacological efficacies, binding 
affinities, and potencies that are several orders of magnitude higher than those of Δ9-THC. 
Of concern is that many of the potent synthetic cannabinoid analogs found in herbal 
preparations are also lipophilic, which increases the likelihood that these compounds cross 
the placenta (Thomas et al., 1990). Furthermore, upon metabolism, many synthetic 
cannabinoids are known to produce an array of secondary bioactive metabolites that also 
display full cannabinoid receptor efficacy (Brents et al., 2012; Fantegrossi et al., 2014; 
Rajasekaran et al., 2013). Taken together, SCBs possess pharmacological properties that 
contribute to health hazards distinct from, or greater than, Δ9-THC, and as such, warrant 
further toxicity testing and characterization.
It is becoming increasingly clear that the endogenous cannabinoid system emerges much 
earlier in vertebrate neurodevelopment than has been commonly recognized. For example, 
CB1 receptor mRNA, functional CB1 receptors, the endocannabinoids AEA, and 2-AG, as 
well as the enzymes involved in their metabolism (NAPE-PLD, DAGLα, DAGLβ MAGL 
and FAAH) were identified in chick embryos as early as Hamburger and Hamilton (HH) 
stage 3 (Psychoyos et al., 2012). Also showing the presence of CB1 receptor expression in 
early chick brain development (HH stage 11+) is work by Begbie et al. (2004) that identified 
the receptor in the primordia of the ventral forebrain, as well as in rhombomeres 4 and 6. 
Extending this work to mammalian systems, and following up on earlier studies of rat 
embryos by Buckley et al. (1998), Psychoyos et al (2012) found a progressive increase in the 
relative levels of CB1 receptor mRNA when comparing expression in samples derived from 
the anterior neural plate of gestational day (GD) 7.5 embryos to the presumptive forebrain of 
GD 8.5, 9.5 and 10.5 C57BL/6J mouse embryos. In addition, this group found that ex ovo 
treatment of gastrulation-stage embryos with the water-soluble cannabinoid O-2545 
interferes with the initial steps of head process and neural plate formation and causes 
abnormal CNS, heart, and somite formation (Psychoyos et al., 2008). These data strongly 
suggest, that as in chick embryos, these early stages of mammalian development will be 
sensitive to SCB-induced birth defects.
The present investigation was designed to test, in a mouse model, the teratogenic potential of 
the SCB agonist, CP-55,940. This compound is a constituent of several Spice varieties 
(Berkovitz et al., 2011), and is one of the most well-characterized and commonly used 
reference compounds in basic cannabinoid research (Tai and Fantegrossi, 2014). For this 
study, GD 8, a known critical period for induction of anterior neural tube defects, ocular, and 
craniofacial malformations, was selected as the time of CP-55,940 exposure. The results of 
this investigation clearly show the mammalian dose-dependent teratogenicity of CP-55,940 
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and strongly support the need for examination of additional critical periods, other SCBs, and 
in-depth mechanistic studies.
2. Materials and Methods
2.1 Animals
All procedures involving animals were approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill, where studies were conducted 
in accordance with NIH and AAALAC guidelines. C57BL/6J mice obtained from The 
Jackson Laboratory (Bar Harbor, ME) were used as subjects in these experiments. The mice 
were maintained on a 12:12 light/dark cycle, and housed under controlled temperature and 
humidity, with free access to water and standard irradiated chow (Prolab Isopro RMH 3000, 
LabDiet, St. Louis, MO). For mating, two nulliparous females were placed with a single 
C57BL/6J male for a maximum of two hours. GD 0.0 was defined as the beginning of the 
breeding period in which a copulation plug was found.
2.2 Immunohistochemistry
For immunohistochemistry, GD 8 embryos were harvested in the uterus and immersion fixed 
in 4% paraformaldehyde. After fixation, intact embryos within their decidua were carefully 
dissected from the uterus, processed using a Leica brand tissue processor and then 
embedded in paraffin. Embryos and decidua were serially sectioned in the sagittal plane at 
10 μm, followed by deparaffination, rehydration, and quenching with H2O2. Steam antigen 
retrieval was performed in combination with an antigen retrieval citra solution (Biogenex, 
Fremont, CA). Rabbit anti-CB1, 1:200 (ABcam, Cambridge, MA) was the primary antibody 
employed. Following incubation with anti-rabbit secondary antibody and avidin/biotin-
immunoperoxidase reactions (Vector Laboratories, Burlingame, CA), antigen was detected 
using diaminobenzidine as a substrate (Innovex Biosciences, Richmond, CA). Photographs 
of sections were taken using an Olympus BX60 light microscope.
2.3 Drug Treatment
On their 8th day of pregnancy, mice were administered CP-55,940 suspended in a vehicle of 
(1:1:18) CP-55,940 in ethanol: Alkamuls El 620 (Rhodia, Cranberry, NJ): lactated Ringer’s 
solution as a single intraperitoneal (i.p.) injection. Control animals at the same stage of 
pregnancy were vehicle treated with a comparable solution that was lacking CP-55,940. 
Injections were administered at a volume of 0.015 ml of solution per gram of maternal body 
weight. Maternal plasma ethanol concentrations were measured in a separate group of mice 
which were treated with vehicle; mean peak plasma ethanol concentrations measuring 43.8 
mg/dl. For drug-response analyses at least 10 litters at each dosage were collected from 
dams treated with 0.0625, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/kg CP-55,940. Single i.p. 
injections of CP-55,940 within this dosage range have previously been shown to evoke the 
characteristic tetrad of cannabinoid-induced behaviors (hypolocomotion, antinociception, 
decrease in rectal temperature, and catalepsy) in mice (Fride et al., 2006; Hamamoto et al., 
2007). The cannabinoid tetrad is considered one of the most widely used assays for 
characterizing overt cannabinoid-induced behaviors in animals, and results are thought to 
closely model physiological responses to cannabinoid receptor activation in humans (Tai and 
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Fantegrossi, 2014). Janoyan and colleagues demonstrated that acute, single i.p. injections of 
CP-55,940 at dosages of 0.5–2.5 mg/kg reverse cannabinoid antagonist-induced head-twitch 
and ear-scratch responses in mice (Janoyan et al., 2002). In their study, the potency profile of 
CP-55,940 in reversing the cannabinoid antagonist-induced behaviors was consistent with its 
published potency for producing the tetrad of behaviors in mice (Compton et al., 1992), as 
well as its published binding affinities for the CB1 and CB2 receptors (Pertwee, 1997). In 
another study by Kow and colleagues, acute i.p. administration of 0.3 mg/kg CP-55,940 
evoked the characteristic behavioral tetrad of effects in wildtype C57Bl/6 mice, but failed to 
do so in mice lacking CB1 receptors (Kow et al., 2014). In the current study, CP-55,940-
induced hypothermia was noted in dams dosed with 2.0 mg/kg, but was not observed at the 
lower dosages tested. To control for hypothermia in the high dose group, immediately 
following drug injection, the cages containing the pregnant mice were placed on a 
temperature-regulated surface to keep body temperatures of the mice at normal levels until 
they were capable of maintaining normothermia on their own (typically four hours). 
Temperature measurements were made using a rectal probe (Braintree Scientific, Braintree, 
MA).
2.4 Fetal Collection and Gross Morphological Analyses
On their 17th day of pregnancy, vehicle and CP-55,940-treated mice were euthanized by 
brief CO2 asphyxiation, followed by cervical dislocation. Gravid uteri were removed, and 
the numbers of live, dead, and resorbed fetuses were recorded. Live fetuses were weighed, 
crown-rump measurements taken, and specimens were collected in individual wells of 
chilled phosphate buffered saline (PBS) followed by examination at the dissecting 
microscopic level for gross morphological abnormalities. Fetuses were then euthanized by 
gradual reduction in body temperature using chilled PBS. Images of each whole fetus and of 
each eye were subsequently captured using a Nikon SMZ—U Stereoscopic Zoom dissecting 
microscope (Nikon Corporation, Melville, NY) and QCapture Suite software (QImaging, 
British Columbia, Canada). Fetuses were then immersion fixed in either 10% formalin or 
Bouin’s solution.
2.5 Histological Analyses
Based on gross externally visible craniofacial malformations, subsets of fetuses were 
selected for routine histological analyses. For this, heads of Bouin’s fixed specimens were 
cleared with 70% ethanol, then auto-processed for paraffin embedding. Serial 10 μm coronal 
sections were cut using a rotary microtome, mounted onto glass slides, and stained with 
hematoxylin and eosin (H&E). Stained sections were examined using an Olympus BX60 
light microscope. Sections from the level of the middle of the eyes and from the level of the 
anterior commissure of the brain were selected for comparison of control and treated 
specimens. Images illustrating secondary palatal defects and a range of ocular and brain 
defects were captured using a MicroPublisher 5.0 digital camera with Real-Time Viewing 
and QCapture Suite software (QImaging, British Columbia, Canada).
2.6 Ocular Dysmorphology and Dose-Response Analyses
Ocular abnormalities at GD 17 were quantitatively assessed following maternal treatment on 
GD 8. Ocular development is highly interrelated with the development and patterning of the 
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prospective forebrain during the gestational period that includes neurulation (corresponding 
to the embryonic stage of CP-55,940 insult in the present investigation), in that the tissues 
that comprise both organs derive from the same region of the anterior neural plate (see Fig. 
1, and (Cook and Sulik, 1986). Ocular defects induced at these early developmental stages, 
thus, typically reflect concurrent insult to the brain. With the most commonly found defects 
in this study involving the eyes, the incidence and severity of readily identifiable ocular 
malformations were utilized as a basis for dose-response analyses. An ocular defect rating 
paradigm modified from Parnell et al., (2006, 2010) was employed. Visual assessments of 
high-resolution digital images of both eyes of each fetus in this study were made by a single 
evaluator who was blinded to treatment. For each eye, a dysmorphology score was assigned 
with categories based on the following criteria: (1) normal globe size, normally shaped 
pupil; (2) apparently normal globe size with abnormally-shaped (but non-colobomatous) 
pupil; (3) mildly microphthalmic with small, abnormally-shaped (but non-colobomatous) 
pupil; (4) moderately microphthalmic with iridio-retinal coloboma; (5) severely 
microphthalmic with iridio-retinal coloboma; (6) severely microphthalmic, absent pupil; (7) 
apparently anophthalmic. Representative images of eyes falling into each of these 7 
categories are shown in Fig. 2. For each fetus the score that reflected the more dysmorphic 
eye was used for dose-response analyses. Control and treatment groups were compared 
statistically as described below.
2.7 Statistics
For each treatment and control group, mean litter sizes, fetal weights, crown-rump lengths, 
and ocular dysmorphology scores were analyzed with GraphPad (version 5.0) using a one-
way analysis of variance (ANOVA) with post-hoc Bonferroni-corrected comparisons, when 
appropriate. Statistical contingency analyses were conducted with SigmaPlot (Version 11.0) 
using Pearson Chi-Square analyses, and single linear regression analyses. For all analyses, 
significance was set at p < 0.05.
3. Results
3.1 CB1 Receptors Are Present in GD 8 Mouse Embryos
As shown in a parasagittal section through a GD 8 mouse embryo (Fig. 1), 
immunohistochemical staining revealed CB1 receptor expression at this early stage in 
embryogenesis. Staining was particularly intense in the pseudostratified epithelium of the 
developing anterior neural plate; tissue that will form the brain and eyes. Staining was also 
evident in cell populations that are progenitors for the developing heart and gut.
3.2 CP-55,940 Induces Craniofacial and Ocular Abnormalities in GD 17 Fetuses Following 
Treatment on GD 8
Presented in Table 1 are litter characteristics for this study. No significant differences were 
found between the GD 17 vehicle-treated control litters and those from all tested CP-55,940 
dosages with respect to average litter size, fetal weight, or crown rump length.
At all CP-55,940 dosages tested, malformations involving the craniofacies and/or eyes were 
induced. Among the externally visible craniofacial defects were micrognathia, facial clefts, 
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facies consistent with holoprosencephaly (median facial deficiency), and exencephaly. The 
range of ocular defects observed include microphthalmia, iridial coloboma, and apparent 
anophthalmia. As shown in Table 1, the above-noted non-ocular craniofacial defects were 
observed in a relatively small number of the CP-55,940-exposed fetuses. The incidence and 
severity of these defects were greater in fetuses exposed to CP-55,940 dosages higher than 
0.5 mg/kg. None of the vehicle-treated control fetuses presented with non-ocular 
malformations. All of the fetuses that had craniofacial defects also had ocular abnormalities. 
Details regarding the incidence and severity of the ocular defects for all of the fetuses in this 
study are shown in Table 2 and are also presented in the dose-response analyses section, 
below.
3.3 Histological Analyses Illustrate CP-55,940-Induced Palatal Clefting and Central Nervous 
System Abnormalities
Examination of coronal histological sections of selected CP-55,940-treated GD 17 fetuses, 
all of which had craniofacial malformations, allowed identification of concurrent brain 
defects (Fig. 3). Varying degrees of holoprosencephaly (Fig. 3D, F) and median forebrain 
tissue abnormality were observed (Fig. 3D, F, H). In addition, clefting of the secondary 
palate was noted in a CP-55,940-treated fetus that had a median facial cleft, and in another 
that had an oblique facial cleft. Also readily apparent in the histological sections of these 
fetuses were a range of ocular defects, some of them being very severe in the CP-55,940-
treated specimens. Highlighted in Fig. 4 is severe cortical dysplasia, which was observed in 
a fetus whose dam had been treated with 2.0 mg/kg CP-55,940.
3.4 CP-55,940 Teratogenesis is Dosage-Dependent
The most commonly found gross dysmorphology in this study involved the eyes, with 
defects ranging from mild microphthalmia with or without colobomata to apparent 
anophthalmia. Employing a 7-point ranking system (with score values increasing as the 
degree of ocular dysmorphology increased; Fig. 2) and visual inspection of high-quality 
digital images by an independent evaluator blinded to treatment, each eye of each control 
and treated fetus was assigned a dysmorphology score. A score greater than one was 
considered abnormal. In the control group, 14.9% of the fetuses had at least one eye that was 
dysmorphic; a finding consistent with the previously-reported C57BL/6J mouse 
predisposition for this type of eye defect (Cook and Sulik, 1986; Parnell et al., 2006; Smith 
et al., 1994b; Tyndall and Cook, 1990). Chi-square analyses revealed that the incidence of 
abnormal ocular morphology increased significantly and in a direct dose-dependent manner 
following exposure to all dosages of CP-55,940 tested; 36.9% at 0.0625 mg/kg CP-55,940, 
(Χ2(1, N = 220) = 13.66, p = 0.0002), 46.4% at 0.125 mg/kg CP-55,940, (Χ2(1, N = 259) = 
30.83, p < 0.0001), 49.4% at 0.25 mg/kg CP-55,940, (Χ2(1, N = 230) = 31.62, p < 0.0001 ), 
59.3% at 0.5 mg/kg CP-55,940 (Χ2(1, N = 238) = 50.92, p < 0.0001), 69.8% at 1.0 mg/kg 
CP-55,940 (Χ2(1, N = 233) = 71.44, p < 0.0001 ), and 81.5% at 2.0 mg/kg CP-55,940 (Χ2(1, 
N = 268) = 63.53, p < 0.0001; see Fig. 5). In order to estimate a dose of CP-55,940 that 
caused an eye defect in 50% of the drug-treated fetuses relative to the spontaneous eye 
defects, a linear regression was performed between the dosages of 0.0625 and 2.0 mg/kg. 
Using the equation Y = 20.97X + 28.56, the ED50 was estimated to be 1.0 mg/kg. A positive 
correlation was found between these two variables, with gestational CP-55,940 treatment 
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accounting for 90% of the variability in ocular dysmorphology observed in the sampled 
population (r2 = 0.90).
As summarized in Table 2, the severity of ocular dysmorphology was also dose-dependent. 
In the vehicle control group, the ocular dysmorphology score never exceeded 3, while the 
more severe defects (ocular dysmorphology score range of 4–7) occurred only in drug-
treated animals. Mean ocular dysmorphology scores for each treatment group were analyzed 
using a 1-way ANOVA, which revealed significant increases in ocular severity in 
cannabinoid-treated versus vehicle control groups [F(6, 679) = 18.23; p < 0.0001, see Table 
2]. Subsequent Bonferroni- corrected analyses revealed that these significant differences in 
ocular severity lie between vehicle-treated fetuses and fetuses exposed to all doses ≥ 0.125 
mg/kg. A linear regression analysis was conducted to further define the correlation between 
mean ocular severity and gestational CP-55,940 exposure. A significant positive correlation 
was found between these two variables, with gestational CP-55,940 treatment, accounting 
for 92% of the variability in ocular dysmorphology observed in the sampled population (r2 = 
0.92).
4. Discussion
The results of this study clearly show that within the range of dosages tested, the synthetic 
cannabinoid agonist CP-55,940 is a mammalian teratogen. The drug-induced defects 
observed involved the craniofacies, eyes, and brain; results that are predictable based on 
insult on GD 8 in mice, when the cranial neural plate and associated facial and ocular tissues 
are beginning to form. This is also the critical period for induction by other teratogens 
including alcohol and retinoic acid of abnormalities comparable to those caused by 
CP-55,940 (Johnston and Bronsky, 1991; Kotch and Sulik, 1992; Padmanabhan and Ahmed, 
1997). The ability of a variety of environmental agents, including commonly abused drugs, 
to cause similar birth defects can be clinically problematic. In helping to determine 
teratogenic mechanisms, however, this type of overlap can provide important clues. As with 
alcohol (Dunty et al., 2001; Kotch and Sulik, 1992) and retinoic acid (Alles and Sulik, 
1992), excessive cell death in early neuroepithelial or neural crest cell populations as the 
pathogenic basis for CP-55,940-induced birth defects is a possibility that requires further 
investigation. Importantly, cannabinoids are known inducers of p53-regulated apoptosis 
through activation of CB1 receptors (Downer et al., 2007; Maccarrone et al., 2014); and p53-
dependent apoptosis in the developing forebrain of GD 8 mouse embryos has been shown to 
result in defective ocular and craniofacial development (Wubah et al., 1996).
While sensitivity to CP-55,940-induced teratogenesis following exposure on GD 8 may or 
may not be cannabinoid receptor-dependent, our illustration of CB1 receptor expression in a 
relevant embryonic cell populations (i.e. the anterior neural plate) at the time of treatment in 
this study supports the possibility of receptor involvement. To confirm this, additional 
mechanism-directed studies, including investigation of the potential of cannabinoid receptor 
antagonism to modify CP-55,940’s teratogenicity, are needed.
Of interest, recent studies by others are suggestive of a direct (non-receptor-dependent) 
teratogenic mechanism involving cannabinoid-induced disruption of cholesterol 
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modification of Sonic Hedgehog (Shh) or perturbation of the downstream Shh pathway 
proteins (Khaliullina et al., 2015; Li et al., 2007). Shh signaling is critical for early brain and 
facial development and alterations in this pathway yield defects comparable to those seen in 
this study (Echelard et al., 1993). During normal Shh signaling, Shh binds to the 
transmembrane protein Patched (Ptc), thereby alleviating Ptc-mediated suppression of the 
signal transducer Smoothened (Smo). Smo activation then triggers a series of intracellular 
events that regulate cellular survival, growth, differentiation, and morphogenesis during 
embryonic development (Alcedo et al., 1996; Chen et al., 2002). Khaliullina and colleagues 
(Khaliullina et al., 2015) have demonstrated that in Drosophila, circulating endogenous 
cannabinoids directly inhibit Shh pathway activation by acting as negative allosteric 
modulators of Smo.
Considering that the processes that regulate mammalian embryonic development are 
relatively conserved across species, along with increasing SCB usage by women of child-
bearing age, and the emergence of increasingly potent SCB analogs, the findings from this 
study raise substantial public health concerns. Importantly, the results of the current 
investigation have shown CP-55,940 teratogenicity in mice following maternal exposure to 
dosage levels that appear to be pharmacologically relevant in humans (FDA, 2005). While 
studies directed toward defining the drug disposition and pharmacological profile resulting 
from the CP-55,940 treatment paradigm used in this investigation are needed, the drug-
induced maternal behavioral and physiological changes noted are consistent with those 
shown by others to follow CB1 receptor agonism in mice. These changes include analgesia, 
catalepsy, decreased rectal temperature, and locomotor suppression and are referred to as the 
cannabinoid tetrad (Janoyan et al., 2002; Smith et al., 1994a). The CP-55,940 dosages used 
in the present study are also within the range of those employed in previously published 
rodent drug discrimination studies (Wiley et al., 1995).
In summary, the renewed interest in SCBs as recreational drugs of abuse has raised 
considerable public health concern, especially in regard to women who are or may become 
pregnant. Emergency rooms and poison control centers are encountering cases of SCB 
toxicity more frequently than ever before; however, there is a paucity of published data 
regarding effects of SCBs on pregnant women and of the potential negative impact of SCBs 
on the developing fetus. Overall, the results reported herein provide novel insight into the 
teratogenic potential of SCBs. Importantly, they indicate that analyses of additional 
developmental periods are warranted, with the expectation that other developmental stage-
dependent, CP-55,940-inducible birth defects will also be identified. This work should serve 
as a catalyst for additional teratology studies evaluating other potent cannabimimetics that 
are being used either alone or in combination with other drugs by women of child-bearing 
age. Basic research, such as that detailed in this study, is clearly needed to address the void 
in knowledge regarding the teratogenicity of SCBs.
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Highlights
• CP-99,540, a synthetic cannabinoid, administered to mice at doses as 
low as
• 0.0625 mg/kg during early pregnancy is teratogenic.
• CP-99,540 dosages at the low end of those found to be teratogenic are 
within
• the realm of potential human exposure.
• Maternal CP-99,540 administration at neurulation stages of 
development result in
• craniofacial, ocular and brain dysmorphology.
• The developmental stages at which CP-99,540 was shown to be 
teratogenic
• occur prior to typical pregnancy recognition in humans.
• These results strongly support the need for more research and 
commensurate prevention-directed public health approaches.
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Figure 1. 
Anti-CB1 receptor immunohistochemistry. Illustrated is a sagittal section through a GD 8 
embryo that was stained with an antibody specific to the CB1 receptor. The arrows indicate 
CB1 expression which appears somewhat segmented in pattern in the neuroepithelium of the 
developing neural plate (precursor of the eyes and brain). The inset is a scanning electron 
micrograph of a GD 8 mouse embryo, with the boxed area showing the sectioned region. 
Scale bar = 100 μm.
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Figure 2. 
Illustrated is a normal eye (1) and a range of CP-55,940-induced dysmorphic eyes (2–7), that 
form the basis for the 7-point scoring system employed in ranking the severity of ocular 
abnormality. For each eye, a dysmorphology score was assigned with categories based on 
the following criteria (1) normal globe size, normally shaped pupil; (2) apparently normal 
globe size with abnormally-shaped (but non-colobomatous) pupil; (3) mildly 
microphthalmic with small, abnormally-shaped (but non-colobomatous) pupil; (4) 
moderately microphthalmic with iridio-retinal coloboma; (5) severely microphthalmic with 
iridio-retinal coloboma; (6) severely microphthalmic, absent pupil. A score of 7 represents 
anophthalmia; thus no eye is present in the last image. Assignment of scores is based on 
visual assessment by an experienced dysmorphologist, with discrimination between groups 
dependent on overall ocular size as well as pupil size and shape.
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Figure 3. 
Histological sections of control (A, B), and CP 55,940-treated GD 17 fetal mice illustrate 
that maternal dosages of 0.5 mg/kg (C–F) and 1.0 mg/kg (G, H) administered on GD 8 yield 
abnormalities of the brain, eyes, palate, and mandible. Figures in the left column are from 
sections made through the center of the eyes (e), while those in the right column are through 
the brain at the level of the anterior commissure (arrow in B). Notable are varying degrees of 
ocular abnormalities involving the right and/or left eyes of the treated animals. Additionally, 
the fetuses shown in E and G each have secondary palatal clefts (compare to the closed 
palate [p] in the control specimen). This is accompanied by a small mandible in the fetus 
shown in E (arrow). The brain abnormalities in the fetuses shown in D–F are most evident in 
the ventral midline (dashed circles) and include septal region defects.
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Figure 4. 
Shown are coronal histological sections from a control GD 17 mouse fetus (A, C), and a 
fetus whose mother was treated with 2.0 mg/kg CP 55,940 on GD 8 (B, D). The boxed areas 
shown in A and B are the cerebrocortical regions shown at higher magnification in C and D, 
respectively. Readily apparent at both low and high magnification is severe dysplasia 
involving the left cerebral hemisphere of the cannabinoid-exposed fetus. The arrow in D is 
directed toward a region of cerebrocortical dysplasia. Scale bar in B = 500μm, and in D = 
200μm.
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Figure 5. 
CP-55,940 dose response analyses illustrate teratogenicity at maternal dosages ranging from 
0.0625 to 2.0 mg/kg. Scoring for ocular defects is based on the severity scale described in 
Fig. 2. Consistent with previous studies, 14.9% of the vehicle-treated mice present with 
spontaneous eye defects, most of which are subtle. As compared to control, CP-55,940 
induced a significantly greater number of eye defects in a dose-dependent manner, with the 
1.0 mg/kg exposure group presenting with ocular defects above vehicle treated levels in 50% 
of the drug-treated animals (p 0.0002).
Gilbert et al. Page 18
Neurotoxicol Teratol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gilbert et al. Page 19
Ta
bl
e 
1
G
ro
ss
 M
or
ph
ol
og
ic
al
 A
na
ly
se
s F
o
llo
w
in
g 
CP
-5
5,
94
0 
Ex
po
su
re
 o
n 
G
D
 8
.
C
P-
55
,9
40
-tr
ea
te
d
Ve
hi
cl
e
0.
06
25
 m
g/
kg
0.
12
5 
m
g/
kg
0.
25
 m
g/
kg
0.
50
 m
g/
kg
1 
m
g/
kg
2 
m
g/
kg
To
ta
l N
um
be
r o
f L
itt
er
s
20
10
15
10
13
11
12
M
ea
n 
Li
tte
r 
Si
ze
 ±
 S
EM
7.
35
 ±
 0
.5
4
7.
30
 ±
 0
.7
8
7.
47
 ±
 0
.3
1
8.
30
 ±
 0
.4
4
7.
00
 ±
 0
.6
3
7.
82
 ±
 0
.6
2
7.
67
 ±
 0
.5
0
To
ta
l R
es
or
pt
io
ns
4
3
3
2
4
2
3
M
ea
n 
Fe
ta
l W
ei
gh
t (
g ±
 SE
M
)
0.
79
 ±
 0
.0
06
0.
79
 ±
 0
.0
08
0.
78
 ±
 0
.0
07
0.
79
 ±
 0
.0
07
0.
81
 ±
 0
 .0
08
0.
80
 ±
 0
.0
08
0.
80
 ±
 0
.0
08
M
ea
n 
C
ro
w
n
-R
um
p 
Le
ng
th
 (m
m 
± S
EM
)
16
.9
 ±
 0
.0
5
17
.0
 ±
 0
.0
7
16
.9
 ±
 0
.0
6
16
.9
 ±
 0
.0
6
17
.1
 ±
 0
.0
7
17
.0
 ±
 0
.0
7
16
.9
 ±
 0
.0
7
N
um
be
r o
f F
et
us
es
 w
ith
 N
on
-o
cu
la
r C
ra
ni
of
ac
ia
l M
al
fo
rm
a
tio
ns
0
11
0
11
61
(3)
,
2(
1),
3(
2)
41
(2)
,
 
3(
2)
10
1(
4),
 
3(
4),
 
4(
1),
5(
1)
1 =
 M
ic
ro
gn
at
hi
a;
2 =
 O
bl
iq
ue
 fa
ci
al
 c
le
ft;
3 =
 H
ol
op
ro
se
nc
ep
ha
ly
;
4 =
 M
ed
ia
n 
fa
ci
al
 c
le
ft;
5 =
 E
xe
n
ce
ph
al
y 
(#)
= n
um
be
r o
f f
etu
ses
 w
ith
 ea
ch
 of
 th
e i
nd
ica
ted
 de
fec
ts
Neurotoxicol Teratol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gilbert et al. Page 20
Ta
bl
e 
2
D
ist
rib
u
tio
n 
of
 F
et
al
 O
cu
la
r D
ys
m
or
ph
ol
og
y 
Sc
or
es
 A
cr
os
s C
P-
55
,9
40
 T
re
at
m
en
t G
ro
up
s.
C
P-
55
,9
40
-tr
ea
te
d
Ey
e 
Sc
or
e
Ve
hi
cl
e
0.
06
25
 m
g/
kg
0.
12
5 
m
g/
kg
0.
25
 m
g/
kg
0.
5 
m
g/
kg
1.
0 
m
g/
kg
2.
0 
m
g/
kg
1
12
5
46
60
42
37
26
17
2
20
24
42
31
46
48
52
3
2
1
6
7
3
8
15
4
0
0
4
2
1
2
4
5
0
2
0
0
1
1
3
6
0
0
0
0
2
1
1
7
0
0
0
1
1
0
0
To
ta
l N
um
be
r o
f F
et
us
es
14
7
73
11
2
83
91
86
92
M
ea
n 
O
cu
la
r D
ys
m
or
ph
ol
og
y 
Sc
or
e 
±
 S
EM
1.
16
 ±
 0
.0
3
1.
47
 ±
 0
.0
9
1.
59
 ±
 0
.0
7
1.
69
 ±
 0
.1
0
1.
82
 ±
 0
.1
1
1.
92
 ±
 0
.1
0
2.
21
 ±
 0
.1
0
Neurotoxicol Teratol. Author manuscript; available in PMC 2017 November 01.
